secwatch / observer
8-K filed December 18, 2025, 6:59 PM ET ticker SONM CIK 0001178697
other material confidence high sentiment neutral materiality 0.75

DNA X, Inc. (SONM): M&A transaction — Sonim issues $1.2M convertible note, acquires DNA X DeFi protocol for 19.99% stock

DNA X, Inc.

item 1.01item 2.01item 2.03item 3.02item 3.03item 8.01item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

DNA X, Inc. incurred convertible notes of $1,200,000 with DNA Holdings Venture, Inc. at 10% per annum maturing December 15, 2026.

Instrument
convertible notes
Principal
$1,200,000
Counterparty
DNA Holdings Venture, Inc.
Rate
10% per annum
Maturity
December 15, 2026
Event
incurrence
Exact text from the filing
issued a convertible promissory note in the original principal amount of $1,200,000 (the “DNA Note”)
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

DNA X, Inc. issued convertible note to DNA Holdings Venture, Inc. for $1,200,000.

Security
convertible note
Purchaser
DNA Holdings Venture, Inc.
Consideration
$1,200,000
Exact text from the filing
On December 15, 2025, Sonim Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with DNA Holdings Venture, Inc. (“DNA Holdings”) and issued a convertible promissory note in the original principal amount of $1,200,000 (the “DNA Note”), in a private placement (the “Offering”).
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

DNA X, Inc. issued 223,201 shares of common stock of common stock to DNA Holdings Venture, Inc. for exchange of the membership interest in DNA X.

Security
common stock
Shares
223,201 shares of common stock
Purchaser
DNA Holdings Venture, Inc.
Consideration
exchange of the membership interest in DNA X
Exact text from the filing
December 15, 2025 223,201 shares of common stock in consideration of the exchange of the membership interest in DNA X.
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

DNA X, Inc. issued 18,423 shares of common stock of common stock to 13D Management, LLC for exchange of $180,000 of the Note.

Security
common stock
Shares
18,423 shares of common stock
Purchaser
13D Management, LLC
Consideration
exchange of $180,000 of the Note
Exact text from the filing
November 17, 2025 18,423 shares of common stock in consideration of the exchange of $180,000 of the Note.
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

DNA X, Inc. issued 148,500 shares of common stock of common stock to 13D Management, LLC for exchange of $629,640 of the Note.

Security
common stock
Shares
148,500 shares of common stock
Purchaser
13D Management, LLC
Consideration
exchange of $629,640 of the Note
Exact text from the filing
December 16, 2025 148,500 shares of common stock in consideration of the exchange of $629,640 of the Note.
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

DNA X, Inc. issued 16,187 shares of common stock of common stock to 13D Management, LLC for exchange of $180,000 of the Note.

Security
common stock
Shares
16,187 shares of common stock
Purchaser
13D Management, LLC
Consideration
exchange of $180,000 of the Note
Exact text from the filing
October 31, 2025 16,187 shares of common stock in consideration of the exchange of $180,000 of the Note.
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

DNA X, Inc. completed an acquisition involving DNA Holdings Venture, Inc. for 223,201 shares of the Company’s common stock, representing 19.99% of the outstanding shares of the Company’s common stock as of the date of issuance (closed 2025-12-15).

Action
acquisition
Counterparty
DNA Holdings Venture, Inc.
Consideration
223,201 shares of the Company’s common stock, representing 19.99% of the outstanding shares of the Company’s common stock as of the date of issuance
Closing
2025-12-15
Exact text from the filing
the Company purchased 100% of the membership interests in DNA X LLC, a Delaware limited liability company, (“DNA X”) for an aggregate purchase price of 223,201 shares of the Company’s common stock, representing 19.99% of the outstanding shares of the Company’s common stock as of the date of issuance.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

DNA X, Inc. entered into Purchase Agreement with DNA Holdings Venture, Inc. valued at $1,200,000 (effective 2025-12-15).

Action
entry
Agreement
equity purchase
Counterparty
DNA Holdings Venture, Inc.
Value
$1,200,000
Effective
2025-12-15
Exact text from the filing
On December 15, 2025, Sonim Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with DNA Holdings Venture, Inc. (“DNA Holdings”) and issued a convertible promissory note in the original principal amount of $1,200,000 (the “DNA Note”)
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

DNA X, Inc. entered into Membership Interest Purchase Agreement with DNA Holdings Venture, Inc. valued at 223,201 shares of the Company’s common stock, representing 19.99% of the outstanding shares (effective 2025-12-15).

Action
entry
Agreement
asset purchase
Counterparty
DNA Holdings Venture, Inc.
Value
223,201 shares of the Company’s common stock, representing 19.99% of the outstanding shares
Effective
2025-12-15
Exact text from the filing
for an aggregate purchase price of 223,201 shares of the Company’s common stock, representing 19.99% of the outstanding shares of the Company’s common stock
View on SEC.gov

41 debt financings filed in the last 30 days. Browse all debt financings →

DNA X, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-25-028292
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.